Preferred Label : pyridines;
MeSH definition : Compounds with a six membered aromatic ring containing NITROGEN. The saturated version
is PIPERIDINES.;
Wikipedia automatic translation : Pyridine;
MeSH annotation : pyridine nucleotides will probably be NAD or NADP;
Wikipedia link : https://en.wikipedia.org/wiki/Pyridine;
Is substance : O;
Origin ID : D011725;
UMLS CUI : C0034255;
Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- 20-438 [MeSH Supplementary Concept]
- 4CP.P [MeSH Supplementary Concept]
- 57G709 [MeSH Supplementary Concept]
- 7-chloro-3-methyl-1,2,3,4,4aalpha,5,9,10,14balpha,14cbeta-decahydropyrido(3'',2''-6',7')cyclohepta(1',2',3'-4,5)naphtho(2,3-c)pyridine [MeSH Supplementary Concept]
- 709W92 [MeSH Supplementary Concept]
- A 1110U [MeSH Supplementary Concept]
- A 76889 [MeSH Supplementary Concept]
- A 79285 [MeSH Supplementary Concept]
- A 80987 [MeSH Supplementary Concept]
- A277249 [MeSH Supplementary Concept]
- ABT-202 [MeSH Supplementary Concept]
- ABT724 [MeSH Supplementary Concept]
- AD 6048 [MeSH Supplementary Concept]
- ADH-41 [MeSH Supplementary Concept]
- AF38469 [MeSH Supplementary Concept]
- AG 2000 [MeSH Supplementary Concept]
- AH 6696 [MeSH Supplementary Concept]
- AHC 93 [MeSH Supplementary Concept]
- AMG 333 [MeSH Supplementary Concept]
- AP 155 [MeSH Supplementary Concept]
- AP80978 [MeSH Supplementary Concept]
- APD597 [MeSH Supplementary Concept]
- APX2039 [MeSH Supplementary Concept]
- AS 35 [MeSH Supplementary Concept]
- ASP4132 [MeSH Supplementary Concept]
- ASP8477 [MeSH Supplementary Concept]
- AST5902 [MeSH Supplementary Concept]
- AU 1421 [MeSH Supplementary Concept]
- AV0012 [MeSH Supplementary Concept]
- AV1013 [MeSH Supplementary Concept]
- AZ3303 [MeSH Supplementary Concept]
- AZD0156 [MeSH Supplementary Concept]
- AZD0865 [MeSH Supplementary Concept]
- AZD1390 [MeSH Supplementary Concept]
- AZD2906 [MeSH Supplementary Concept]
- AZD3409 [MeSH Supplementary Concept]
- AZD6538 [MeSH Supplementary Concept]
- AZD6765 [MeSH Supplementary Concept]
- AZD9272 [MeSH Supplementary Concept]
- AZD9362 [MeSH Supplementary Concept]
- AZD9567 [MeSH Supplementary Concept]
- BC-1215 [MeSH Supplementary Concept]
- BDP9066 [MeSH Supplementary Concept]
- BI 414 [MeSH Supplementary Concept]
- BIBN 99 [MeSH Supplementary Concept]
- BIMG 80 [MeSH Supplementary Concept]
- BJ-3105 [MeSH Supplementary Concept]
- BM 20 [MeSH Supplementary Concept]
- BMS202 [MeSH Supplementary Concept]
- BPDZ 44 [MeSH Supplementary Concept]
- BPDZ 62 [MeSH Supplementary Concept]
- BRD5529 [MeSH Supplementary Concept]
- BRLP 42 [MeSH Supplementary Concept]
- BRX 005 [MeSH Supplementary Concept]
- BY 841 [MeSH Supplementary Concept]
- CB 34 [MeSH Supplementary Concept]
- CB 50 [MeSH Supplementary Concept]
- CB 54 [MeSH Supplementary Concept]
- CB 7645 [MeSH Supplementary Concept]
- CC41801 [MeSH Supplementary Concept]
- CDP 840 [MeSH Supplementary Concept]
- CGH2466 [MeSH Supplementary Concept]
- CI 966 [MeSH Supplementary Concept]
- CI 969 [MeSH Supplementary Concept]
- CM 188 [MeSH Supplementary Concept]
- CMG002 [MeSH Supplementary Concept]
- CMPD101 [MeSH Supplementary Concept]
- CP 113 [MeSH Supplementary Concept]
- CPBMF65 [MeSH Supplementary Concept]
- CPC 222 [MeSH Supplementary Concept]
- CPD0905 [MeSH Supplementary Concept]
- CRA1000 [MeSH Supplementary Concept]
- CSI-75 [MeSH Supplementary Concept]
- CT 2450 [MeSH Supplementary Concept]
- CW008 [MeSH Supplementary Concept]
- CX509 [MeSH Supplementary Concept]
- CYT997 [MeSH Supplementary Concept]
- DB 750 [MeSH Supplementary Concept]
- DC07090 [MeSH Supplementary Concept]
- DCZ3301 [MeSH Supplementary Concept]
- DDP733 [MeSH Supplementary Concept]
- DFX24 [MeSH Supplementary Concept]
- DR-4004 [MeSH Supplementary Concept]
- DRK092 [MeSH Supplementary Concept]
- DS-6930 [MeSH Supplementary Concept]
- DTTX30 [MeSH Supplementary Concept]
- E 3040 [MeSH Supplementary Concept]
- E 3709 [MeSH Supplementary Concept]
- E 4031 [MeSH Supplementary Concept]
- E 5555 [MeSH Supplementary Concept]
- E 5842 [MeSH Supplementary Concept]
- EF 4025 [MeSH Supplementary Concept]
- EL 241 [MeSH Supplementary Concept]
- F 16915 [MeSH Supplementary Concept]
- FG 5938 [MeSH Supplementary Concept]
- FI-700 [MeSH Supplementary Concept]
- FIT-039 [MeSH Supplementary Concept]
- FK 352 [MeSH Supplementary Concept]
- FK 453 [MeSH Supplementary Concept]
- FK 838 [MeSH Supplementary Concept]
- FP-TZTP [MeSH Supplementary Concept]
- FX 2212 [MeSH Supplementary Concept]
- FYX-051 [MeSH Supplementary Concept]
- GANT 61 [MeSH Supplementary Concept]
- GANT58 [MeSH Supplementary Concept]
- GNE-781 [MeSH Supplementary Concept]
- GNE-924 [MeSH Supplementary Concept]
- GRN-529 [MeSH Supplementary Concept]
- GS-680 [MeSH Supplementary Concept]
- GS-CA1 [MeSH Supplementary Concept]
- GSK5750 [MeSH Supplementary Concept]
- GSK8853 [MeSH Supplementary Concept]
- HA 1363 [MeSH Supplementary Concept]
- HA 1495 [MeSH Supplementary Concept]
- HA 1568 [MeSH Supplementary Concept]
- HBSC11 [MeSH Supplementary Concept]
- HI 236 [MeSH Supplementary Concept]
- HI 240 [MeSH Supplementary Concept]
- HI 244 [MeSH Supplementary Concept]
- HI 253 [MeSH Supplementary Concept]
- HI 443 [MeSH Supplementary Concept]
- HI 445 [MeSH Supplementary Concept]
- HMN 154 [MeSH Supplementary Concept]
- HNS 32 [MeSH Supplementary Concept]
- HO3073 [MeSH Supplementary Concept]
- HPH-Pep [MeSH Supplementary Concept]
- HR 780 [MeSH Supplementary Concept]
- HS-104 [MeSH Supplementary Concept]
- HS-106 [MeSH Supplementary Concept]
- HS-116 [MeSH Supplementary Concept]
- HSR 609 [MeSH Supplementary Concept]
- IBL-302 [MeSH Supplementary Concept]
- IHC 64 [MeSH Supplementary Concept]
- IRP 6 [MeSH Supplementary Concept]
- IS 741 [MeSH Supplementary Concept]
- IT 066 [MeSH Supplementary Concept]
- JB-788 [MeSH Supplementary Concept]
- JMS-053 [MeSH Supplementary Concept]
- JNJ4796 [MeSH Supplementary Concept]
- JSM6427 [MeSH Supplementary Concept]
- JTE 013 [MeSH Supplementary Concept]
- JTT 606 [MeSH Supplementary Concept]
- KD 5170 [MeSH Supplementary Concept]
- KDI 792 [MeSH Supplementary Concept]
- KDU731 [MeSH Supplementary Concept]
- KI 3315 [MeSH Supplementary Concept]
- KI 4032 [MeSH Supplementary Concept]
- KMH-233 [MeSH Supplementary Concept]
- KUS121 [MeSH Supplementary Concept]
- KX2 329 [MeSH Supplementary Concept]
- KX2-361 [MeSH Supplementary Concept]
- L797591 [MeSH Supplementary Concept]
- LBK 10 [MeSH Supplementary Concept]
- LBK 38 [MeSH Supplementary Concept]
- LEI121 [MeSH Supplementary Concept]
- LGH-447 [MeSH Supplementary Concept]
- LGK974 [MeSH Supplementary Concept]
- LN950 [MeSH Supplementary Concept]
- LUF7244 [MeSH Supplementary Concept]
- M55529 [MeSH Supplementary Concept]
- MBX2319 [MeSH Supplementary Concept]
- MDB5 [MeSH Supplementary Concept]
- ME 3407 [MeSH Supplementary Concept]
- MGV354 [MeSH Supplementary Concept]
- MIV 150 [MeSH Supplementary Concept]
- MK 761 [MeSH Supplementary Concept]
- MK 996 [MeSH Supplementary Concept]
- MK-1597 [MeSH Supplementary Concept]
- MK-1832 [MeSH Supplementary Concept]
- MK-2295 [MeSH Supplementary Concept]
- MK-3328 [MeSH Supplementary Concept]
- MK-3697 [MeSH Supplementary Concept]
- MK-8353 [MeSH Supplementary Concept]
- MK-8722 [MeSH Supplementary Concept]
- MK-8825 [MeSH Supplementary Concept]
- MK-9470 [MeSH Supplementary Concept]
- MKT 077 [MeSH Supplementary Concept]
- ML253 [MeSH Supplementary Concept]
- MLN3897 [MeSH Supplementary Concept]
- MP 115 [MeSH Supplementary Concept]
- MSA 300 [MeSH Supplementary Concept]
- MSC 127 [MeSH Supplementary Concept]
- MYCMI-6 [MeSH Supplementary Concept]
- N-(pyridine-3-ylmethyl)-5-(7-hydroxy-2,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-yl)-2-methylpenta-2,4-dienamide [MeSH Supplementary Concept]
- NCT-503 [MeSH Supplementary Concept]
- NOR 4 [MeSH Supplementary Concept]
- NX-13 [MeSH Supplementary Concept]
- ODM-207 [MeSH Supplementary Concept]
- OR-2100 [MeSH Supplementary Concept]
- OSI-296 [MeSH Supplementary Concept]
- OT-82 [MeSH Supplementary Concept]
- P 1188 [MeSH Supplementary Concept]
- P3155 [MeSH Supplementary Concept]
- PAPHY [MeSH Supplementary Concept]
- PETT 1 [MeSH Supplementary Concept]
- PETT 2 [MeSH Supplementary Concept]
- PF 3845 [MeSH Supplementary Concept]
- PF-114 [MeSH Supplementary Concept]
- PFK15 [MeSH Supplementary Concept]
- PFK158 [MeSH Supplementary Concept]
- PI-2620 [MeSH Supplementary Concept]
- PI103 [MeSH Supplementary Concept]
- PMP-311 [MeSH Supplementary Concept]
- PPA 250 [MeSH Supplementary Concept]
- PPO 464 [MeSH Supplementary Concept]
- PQR530 [MeSH Supplementary Concept]
- PS1145 [MeSH Supplementary Concept]
- PSS223 [MeSH Supplementary Concept]
- PSS232 [MeSH Supplementary Concept]
- PT-1284 [MeSH Supplementary Concept]
- PY 608 [MeSH Supplementary Concept]
- PdpaMn [MeSH Supplementary Concept]
- R 58639 [MeSH Supplementary Concept]
- RAF265 [MeSH Supplementary Concept]
- RX-111 [MeSH Supplementary Concept]
- RepSox [MeSH Supplementary Concept]
- S 3025 [MeSH Supplementary Concept]
- S 4048 [MeSH Supplementary Concept]
- S32006 [MeSH Supplementary Concept]
- S35972 [MeSH Supplementary Concept]
- SA00025 [MeSH Supplementary Concept]
- SAG1.3 [MeSH Supplementary Concept]
- SAR405 [MeSH Supplementary Concept]
- SB2001 [MeSH Supplementary Concept]
- SCO-267 [MeSH Supplementary Concept]
- SCR2682 [MeSH Supplementary Concept]
- SH 306 [MeSH Supplementary Concept]
- SH7129 [MeSH Supplementary Concept]
- SH7139 [MeSH Supplementary Concept]
- SJ749 [MeSH Supplementary Concept]
- SL-2-25 [MeSH Supplementary Concept]
- SMe1EC2 [MeSH Supplementary Concept]
- SN 6570 [MeSH Supplementary Concept]
- SN003 [MeSH Supplementary Concept]
- SPI 447 [MeSH Supplementary Concept]
- SSJ 183 [MeSH Supplementary Concept]
- STF-31 [MeSH Supplementary Concept]
- T 0162 [MeSH Supplementary Concept]
- T 0970 [MeSH Supplementary Concept]
- T 1032 [MeSH Supplementary Concept]
- T 2585 [MeSH Supplementary Concept]
- T 330 [MeSH Supplementary Concept]
- TA 606 [MeSH Supplementary Concept]
- TA-3404 [MeSH Supplementary Concept]
- TAK-137 [MeSH Supplementary Concept]
- TAK-441 [MeSH Supplementary Concept]
- TAK-915 [MeSH Supplementary Concept]
- TASP457 [MeSH Supplementary Concept]
- TC 2559 [MeSH Supplementary Concept]
- TC-8581 [MeSH Supplementary Concept]
- TGN-073 [MeSH Supplementary Concept]
- TJN-259 [MeSH Supplementary Concept]
- TKI-30 [MeSH Supplementary Concept]
- TKI-31 [MeSH Supplementary Concept]
- TT-301 [MeSH Supplementary Concept]
- TT-OAD2 [MeSH Supplementary Concept]
- UBS109 [MeSH Supplementary Concept]
- UK 2A [MeSH Supplementary Concept]
- UK 2B [MeSH Supplementary Concept]
- UK 2C [MeSH Supplementary Concept]
- UK 2D [MeSH Supplementary Concept]
- UK-3A [MeSH Supplementary Concept]
- UNC7938 [MeSH Supplementary Concept]
- UP-91 [MeSH Supplementary Concept]
- UR-1102 [MeSH Supplementary Concept]
- V 10367 [MeSH Supplementary Concept]
- VT-1129 [MeSH Supplementary Concept]
- VT-1161 [MeSH Supplementary Concept]
- VT-1598 [MeSH Supplementary Concept]
- WL 19 [MeSH Supplementary Concept]
- WP 1193 [MeSH Supplementary Concept]
- WP1066 [MeSH Supplementary Concept]
- X 9121 [MeSH Supplementary Concept]
- XG 696 [MeSH Supplementary Concept]
- Y 19995 [MeSH Supplementary Concept]
- Y 25510 [MeSH Supplementary Concept]
- Y 27632 [MeSH Supplementary Concept]
- Y 30141 [MeSH Supplementary Concept]
- Y 32885 [MeSH Supplementary Concept]
- Y 9000 [MeSH Supplementary Concept]
- Y-33075 [MeSH Supplementary Concept]
- Y-39983 [MeSH Supplementary Concept]
- YH-GKA [MeSH Supplementary Concept]
- YM 461 [MeSH Supplementary Concept]
- YM 976 [MeSH Supplementary Concept]
- ZD 9583 [MeSH Supplementary Concept]
- ZED1227 [MeSH Supplementary Concept]
- ZnAF-1 [MeSH Supplementary Concept]
- ZnAF-2 [MeSH Supplementary Concept]
- aleicid [MeSH Supplementary Concept]
- alpidem [MeSH Supplementary Concept]
- azd9684 [MeSH Supplementary Concept]
- bananin [MeSH Supplementary Concept]
- diethyl -1,5-dibenzyl-1,5,8,8b-tetrahydro-4a,8a-dihydroxymethyl-4,8-diphenyl-cyclobuta(1,2b,3,4b')dipyridine-3,7(4H,4bH)dicarboxylate [MeSH Supplementary Concept]
- diethyl 1,5-dibenzyl-1,5,8,8b-tetrahydro-4a,8a-dihydroxymethyl-4,8-bis(4-methoxyphenyl)-cyclobuta(1,2b,3,4b')dipyridine-3,7(4H,4bH)dicarboxylate [MeSH Supplementary Concept]
- emopag [MeSH Supplementary Concept]
- iCRT14 [MeSH Supplementary Concept]
- ki 1769 [MeSH Supplementary Concept]
- ki 3005 [MeSH Supplementary Concept]
- mefway [MeSH Supplementary Concept]
- nifene [MeSH Supplementary Concept]
- pitaf [MeSH Supplementary Concept]
- pqr620 [MeSH Supplementary Concept]
- su 9055 [MeSH Supplementary Concept]
- tachpyr [MeSH Supplementary Concept]
- See also
- Semantic type(s)
- UMLS correspondences (same concept)
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version
is PIPERIDINES.
https://ansm.sante.fr/tableau-acces-derogatoire/selpercatinib-20-40-et-80mg-gelule
2024
false
false
false
France
French
selpercatinib
administration, oral
carcinoma, non-small-cell lung
advanced RET fusion-positive non-small cell lung cancer
Product containing only selpercatinib in oral dose form (medicinal product form)
drug information
selpercatinib
pyrazoles
pyridines
---
https://ansm.sante.fr/tableau-atu-rtu/sotorasib-120-mg-comprimes-pellicules
2023
false
false
false
France
French
administration, oral
guidelines for drug use
sotorasib
sotorasib
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
bronchial neoplasms
bronchial neoplasms
summary of product characteristics
package leaflet
adult
neoplasm metastasis
sotorasib
piperazines
pyridines
pyrimidines
piperazines
pyridines
pyrimidines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tirbanibulin
tirbanibulin
drug approval
europe
tirbanibulin
administration, cutaneous
ointments
keratosis, actinic
scalp dermatoses
facial dermatoses
enzyme inhibitors
enzyme inhibitors
drug monitoring
adult
aged
pregnancy
breast feeding
tubulin
drug evaluation, preclinical
acetamides
morpholines
pyridines
acetamides
morpholines
pyridines
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/default-d6182e9e12-99.html
2021
false
false
false
Canada
French
drug evaluation
quebec
cystic fibrosis
adolescent
adult
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance
regulator gene
CFTR delta F508
drug combinations
trikafta
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
benzodioxoles
aminophenols
indoles
pyrazoles
pyridines
quinolines
benzodioxoles
aminophenols
drug combinations
indoles
pyrazoles
pyridines
quinolines
---
https://ansm.sante.fr/tableau-atu-rtu/gavreto-100-mg-gelule
2021
false
false
false
France
French
pralsetinib
guidelines for drug use
pralsetinib
pyrazoles
pyridines
pyrimidines
---
https://www.has-sante.fr/jcms/p_3265513/fr/isturisa-osilodrostat
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
Osilodrostat
Osilodrostat
osilodrostat
administration, oral
adult
cushing syndrome
Endogenous Cushing Syndrome
evaluation of the transparency committee
imidazoles
pyridines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
pyrazoles
pyrazoles
pyridines
pyridines
RET Inhibitor
RET Inhibitor
protein kinase inhibitors
protein kinase inhibitors
Proto-Oncogene Proteins c-ret
antineoplastic agents
antineoplastic agents
product surveillance, postmarketing
RET Gene Mutation
carcinoma, non-small-cell lung
mutation
carcinoma, non-small-cell lung
bronchial neoplasms
Advanced Lung Non-Small Cell Carcinoma
adult
adolescent
thyroid neoplasms
Advanced Thyroid Gland Medullary Carcinoma
Advanced Thyroid Gland Carcinoma
mutagenicity tests
administration, oral
aged
drug interactions
pregnancy
breast feeding
selpercatinib
drug evaluation, preclinical
selpercatinib
selpercatinib
Product containing precisely selpercatinib 40 milligram/1 each conventional release
oral capsule (clinical drug)
Product containing precisely selpercatinib 80 milligram/1 each conventional release
oral capsule (clinical drug)
advanced RET fusion-positive non-small cell lung cancer
advanced RET fusion-positive thyroid cancer
Tyrosine Kinase Inhibitors
---
https://www.has-sante.fr/jcms/p_3242562/jyseleca
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
filgotinib
filgotinib
filgotinib
administration, oral
female
arthritis, rheumatoid
Janus Kinase Inhibitors
Janus Kinase Inhibitors
evaluation of the transparency committee
GLPG0634
GLPG0634
pyridines
triazoles
pyridines
triazoles
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
oxazoles
oxazoles
pyridines
pyridines
quinazolines
quinazolines
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
tucatinib
receptor, erbB-2
risk management
product surveillance, postmarketing
breast neoplasms
neoplasm metastasis
HER2-positive metastatic breast cancer
antineoplastic combined chemotherapy protocols
Capecitabine/Trastuzumab/Tucatinib Regimen
administration, oral
adult
aged
continuity of patient care
drug interactions
pregnancy
breast feeding
survival analysis
drug evaluation, preclinical
tucatinib
tucatinib
HER2-Positive Breast Carcinoma
Tyrosine Kinase Inhibitors
---
https://www.ema.europa.eu/en/medicines/human/EPAR/xofluza
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
baloxavir marboxil
baloxavir marboxil
baloxavir marboxil
antiviral agents
antiviral agents
enzyme inhibitors
enzyme inhibitors
product surveillance, postmarketing
administration, oral
adolescent
adult
aged
influenza, human
influenza, human
Post-Exposure prophylaxis
drug interactions
pregnancy
breast feeding
prodrugs
endonucleases
drug evaluation, preclinical
Product containing only baloxavir marboxil in oral dose form (medicinal product form)
baloxavir
baloxavir
oxazines
pyridines
thiepins
triazines
oxazines
pyridines
thiepins
triazines
---
https://ansm.sante.fr/tableau-atu-rtu/tucatinib-50-mg-comprime-pellicule
2021
false
false
false
France
French
administration, oral
summary of product characteristics
package leaflet
guidelines for drug use
antineoplastic agents
protein kinase inhibitors
tucatinib
Tucatinib
Tucatinib
oxazoles
pyridines
quinazolines
antineoplastic combined chemotherapy protocols
adult
breast neoplasms
Trastuzumab
Capecitabine
Capecitabine/Trastuzumab/Tucatinib Regimen
neoplasm metastasis
receptor, erbB-2
tucatinib
tucatinib
HER2-Positive Breast Carcinoma
oxazoles
pyridines
quinazolines
---
https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/infovigilance-produits-sante/juillet-2021.html#a6
2021
false
false
false
Canada
French
drug information
canada
Product containing precisely pralsetinib 100 milligram/1 each conventional release
oral capsule (clinical drug)
pralsetinib
lung neoplasms
pralsetinib
pyrazoles
pyridines
pyrimidines
---
https://www.has-sante.fr/jcms/p_3273459/fr/tukysa-tucatinib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
tucatinib
antineoplastic agents
protein kinase inhibitors
tucatinib
antineoplastic combined chemotherapy protocols
Trastuzumab
Capecitabine
Capecitabine/Trastuzumab/Tucatinib Regimen
adult
breast neoplasms
HER2-Positive Breast Carcinoma
evaluation of the transparency committee
oxazoles
pyridines
quinazolines
---
https://www.has-sante.fr/jcms/p_3271751/fr/retsevmo-selpercatinib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
selpercatinib
administration, oral
RET Inhibitor
protein kinase inhibitors
antineoplastic agents
Proto-Oncogene Proteins c-ret
selpercatinib
Product containing precisely selpercatinib 80 milligram/1 each conventional release
oral capsule (clinical drug)
Product containing precisely selpercatinib 40 milligram/1 each conventional release
oral capsule (clinical drug)
adult
carcinoma, non-small-cell lung
Advanced Lung Non-Small Cell Carcinoma
adolescent
Advanced Thyroid Gland Medullary Carcinoma
thyroid neoplasms
RET Gene Mutation
carcinoma, non-small-cell lung
thyroid neoplasms
RET Fusion Positive
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
pyrazoles
pyridines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/isturisa
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Osilodrostat
Osilodrostat
osilodrostat
orphan drug production
adult
cushing syndrome
administration, oral
steroid 11-beta-hydroxylase
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
imidazoles
pyridines
imidazoles
pyridines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tavlesse
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
fostamatinib
fostamatinib
fostamatinib
chronic disease
adult
purpura, thrombocytopenic, idiopathic
administration, oral
Syk Kinase
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
oxazines
pyridines
oxazines
pyridines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form
(medicinal product form)
drug approval
europe
drug combinations
administration, oral
orphan drug production
pyrazoles
pyrazoles
pyridines
pyridines
pyrrolidines
pyrrolidines
ivacaftor
ivacaftor
tezacaftor
tezacaftor
adolescent
adult
cystic fibrosis
drug therapy, combination
cystic fibrosis transmembrane conductance regulator
ivacaftor, tezacaftor and elexacaftor
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
elexacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance
regulator gene
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles
indoles
benzodioxoles
quinolines
quinolines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
filgotinib
filgotinib
filgotinib
adult
arthritis, rheumatoid
administration, oral
drug therapy, combination
methotrexate
Janus Kinase Inhibitors
Janus Kinase Inhibitors
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
GLPG0634
GLPG0634
pyridines
triazoles
pyridines
triazoles
---
https://www.has-sante.fr/jcms/p_3220388/fr/kaftrio-/-kalydeco
2020
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
ivacaftor
Chloride Channel Agonists
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
cystic fibrosis
adolescent
adult
CFTR delta F508
cystic fibrosis transmembrane conductance regulator delta F508
administration, oral
elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
evaluation of the transparency committee
aminophenols
quinolones
indoles
benzodioxoles
cystic fibrosis transmembrane conductance regulator
pyrrolidines
pyridines
pyrazoles
drug combinations
quinolines
---
https://www.has-sante.fr/jcms/p_3226885/fr/tavlesse
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
fostamatinib
fostamatinib
fostamatinib
Syk Kinase
Tyrosine Kinase Inhibitor
protein kinase inhibitors
protein kinase inhibitors
adult
chronic disease
purpura, thrombocytopenic, idiopathic
Product containing only fostamatinib in oral dose form (medicinal product form)
guidelines for drug use
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
oxazines
pyridines
oxazines
pyridines
---
https://www.has-sante.fr/jcms/p_3224928/fr/akynzeo
2020
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
insurance, health, reimbursement
netupitant, palosentron drug combination
palonosetron, combinations
antiemetics
nausea
vomiting
antineoplastic agents
nausea
vomiting
adult
isoquinolines
pyridines
quinuclidines
---
https://www.has-sante.fr/jcms/c_2964747/fr/ibrance
2019
false
false
false
France
treatment outcome
palbociclib
antineoplastic agents
protein kinase inhibitors
palbociclib
antineoplastic combined chemotherapy protocols
Letrozole
postmenopause
breast neoplasms
Fulvestrant
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
evaluation of the transparency committee
piperazines
pyridines
---
https://pharmactuel.com/index.php/pharmactuel/article/view/1261
2019
false
false
false
Canada
neoplasms
Factor Xa Inhibitors
edoxaban
critical appraisal or critical reading
comparative effectiveness research
dalteparin
anticoagulants
journal article
venous thromboembolism
edoxaban
pyridines
thiazoles
---
https://www.has-sante.fr/jcms/c_2964747/fr/ibrance-palbociclib-inhibiteur-de-proteine-kinase
2019
false
false
false
France
guidelines for drug use
protein kinase inhibitors
palbociclib
antineoplastic combined chemotherapy protocols
Letrozole
breast neoplasms
Hormone receptor positive malignant neoplasm of breast (disorder)
Human epidermal growth factor 2 negative carcinoma of breast (disorder)
administration, oral
postmenopause
evaluation of the transparency committee
palbociclib
piperazines
pyridines
piperazines
pyridines
---
https://www.has-sante.fr/jcms/p_3082106/fr/cabometyx
2019
false
false
false
France
evaluation of the transparency committee
cabozantinib
adult
treatment outcome
carcinoma, hepatocellular
cabozantinib
administration, oral
antineoplastic agents
protein kinase inhibitors
anilides
pyridines
---
https://ansm.sante.fr/informations-de-securite/Anticoagulants-Oraux-Directs-AODs-apixaban-Eliquis-R-rivaroxaban-Xarelto-R-dabigatran-Pradaxa-R-et-edoxaban-Lixiana-R-Roteas-R-non-recommandes-chez-les-patients-presentant-un-Syndrome-des-Antiphospholipides-SAPL
2019
false
false
false
France
French
pharmacovigilance note
guidelines for drug use
administration, oral
apixaban
Rivaroxaban
edoxaban
anticoagulants
Dabigatran
recurrence
risk
antiphospholipid syndrome
thrombosis
thrombosis
pyrazoles
pyridones
pyridines
thiazoles
---
https://www.has-sante.fr/portail/jcms/c_2964747/fr/ibrance
2019
false
false
false
France
French
palbociclib
antineoplastic agents
protein kinase inhibitors
breast neoplasms
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic combined chemotherapy protocols
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
survival analysis
Progression-Free survival
Human epidermal growth factor 2 negative carcinoma of breast (disorder)
treatment outcome
evaluation of the transparency committee
postmenopause
Stage IV Breast Cancer AJCC v6 and v7
Locally advanced breast cancer
HER2/Neu Negative
palbociclib
piperazines
pyridines
disease-free survival
Progression-Free Survival
---
https://www.has-sante.fr/portail/jcms/c_2908453/fr/cabometyx
https://www.has-sante.fr/portail/jcms/c_2908453/fr/cabometyx-cabozantinib-inhibiteur-de-tyrosine-kinase
2019
false
false
false
false
France
French
treatment outcome
cabozantinib
carcinoma, renal cell
adult
cabozantinib
antineoplastic agents
protein kinase inhibitors
administration, oral
guidelines for drug use
evaluation of the transparency committee
anilides
pyridines
---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-VEGFR-axitinib-cabozantinib-pazopanib-sorafenib-sunitinib
2019
false
false
false
France
Axitinib
cabozantinib
pazopanib
Sorafenib
Sunitinib
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
risk factors
patient education as topic
continuity of patient care
administration, oral
receptors, vascular endothelial growth factor
carcinoma, renal cell
drug interactions
pregnancy
Tyrosine Kinase Inhibitors
guidelines for drug use
Sorafenib
pazopanib
Axitinib
Sunitinib
cabozantinib
pyrimidines
sulfonamides
anilides
pyridines
pyrimidines
sulfonamides
anilides
pyridines
anilides
pyridines
pyrimidines
sulfonamides
---
Extension d'indication
https://www.has-sante.fr/portail/jcms/c_2825855/fr/stivarga-chc
2018
false
France
French
regorafenib
regorafenib
regorafenib
administration, oral
treatment outcome
insurance, health, reimbursement
adult
antineoplastic agents
antineoplastic agents
evaluation of the transparency committee
carcinoma, hepatocellular
phenylurea compounds
pyridines
phenylurea compounds
pyridines
---
http://conseil-scientifique.public.lu/fr/publications/oncologie/regorafenib-mise-a-jour-2018.html
2018
false
false
true
Luxembourg
French
guidelines for drug use
adult
regorafenib
regorafenib
administration, oral
colorectal neoplasms
neoplasm metastasis
Metastatic colorectal cancer
gastrointestinal stromal tumors
disease progression
carcinoma, hepatocellular
protein kinase inhibitors
antineoplastic agents
survival analysis
phenylurea compounds
pyridines
---
https://www.has-sante.fr/portail/jcms/c_2851086/fr/les-anticoagulants-oraux
2018
false
false
false
France
French
guidelines for drug use
anticoagulants
anticoagulants
administration, oral
antivitamins K
antivitamins K
atrial fibrillation
drug overdose
apixaban
Dabigatran
antithrombins
Factor Xa Inhibitors
Rivaroxaban
edoxaban
Direct factor Xa inhibitors
direct thrombin inhibitors
pregnancy
patient compliance
continuity of patient care
hemorrhage
surgical procedures, operative
blood loss, surgical
hemorrhage
vitamin k antagonists
fluindione
acenocoumarol
warfarin
pyridines
thiazoles
phenindione
phenindione
indenes
4-hydroxycoumarins
vitamin K
vitamin K
indenes
4-hydroxycoumarins
vitamin K
pyrazoles
pyridones
---
https://ansm.sante.fr/tableau-marr/vismodegib
2018
false
false
false
France
French
patient education handout
risk management
vismodegib
pregnancy
handbooks
contraception
teratogens
pregnancy tests
vismodegib
forms
abnormalities, drug-induced
fertility
fetal death
embryo death
HhAntag691
embryo loss
anilides
pyridines
---
https://ansm.sante.fr/tableau-marr/sonidegib
2018
false
false
false
France
French
risk management
sonidegib
sonidegib
teratogens
pregnancy
abnormalities, drug-induced
contraception
pregnancy tests
antineoplastic agents
fetal death
patient education handout
scientific and technical information
sonidegib
biphenyl compounds
pyridines
---
https://www.has-sante.fr/portail/jcms/c_2826827/fr/lixiana
2018
false
false
false
France
French
English
treatment outcome
edoxaban
Edoxaban Tosylate
administration, oral
stroke
embolism
adult
risk factors
atrial fibrillation
deep vein thrombosis
deep vein thrombosis
recurrence
pulmonary embolism
pulmonary embolism
hemorrhage
edoxaban
hemorrhage
Factor Xa Inhibitors
edoxaban
evaluation of the transparency committee
venous thrombosis
venous thrombosis
pyridines
thiazoles
pyridines
thiazoles
---
Summary Basis of Decision (SBD) for Bepreve
Bepotastine besilate, 1.5% w/v, solution, ophthalmic
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00324
2017
false
false
false
Canada
French
English
drug information
administration, ophthalmic
bepotastine besilate
Product containing precisely bepotastine besilate 15 milligram/1 milliliter conventional
release eye solution (clinical drug)
piperidines
pyridines
---
http://www.has-sante.fr/portail/jcms/c_2748751/fr/stilnox
2017
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
zolpidem tartrate
zolpidem
pyridines
Zolpidem
---
http://www.has-sante.fr/portail/jcms/c_2755488/fr/akynzeo
https://www.has-sante.fr/portail/jcms/c_2755488/fr/akynzeo-palonosetron-netupitant-setron-en-association
2017
false
false
false
France
French
treatment outcome
drug combinations
netupitant
palonosetron, combinations
palonosetron hydrochloride
nausea
nausea
antineoplastic agents
vomiting
vomiting
administration, oral
serotonin 5-HT3 receptor antagonists
Neurokinin-1 receptor antagonists
netupitant, palosentron drug combination
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
pyridines
isoquinolines
quinuclidines
Palonosetron
---
https://www.ema.europa.eu/medicines/human/EPAR/Roteas
2017
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
edoxaban
edoxaban
Edoxaban Tosylate
Edoxaban Tosylate
drug approval
europe
product surveillance, postmarketing
administration, oral
stroke
embolism
adult
risk factors
atrial fibrillation
deep vein thrombosis
deep vein thrombosis
recurrence
pulmonary embolism
pulmonary embolism
drug interactions
pregnancy
breast feeding
hemorrhage
Edoxaban Tosylate
hemorrhage
Factor Xa Inhibitors
Factor Xa Inhibitors
edoxaban
drug evaluation, preclinical
drug evaluation
venous thrombosis
venous thrombosis
pyridines
thiazoles
pyridines
thiazoles
---
https://www.has-sante.fr/portail/jcms/c_2761877/fr/ibrance
2017
false
false
false
France
French
palbociclib
antineoplastic agents
protein kinase inhibitors
breast neoplasms
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic combined chemotherapy protocols
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
survival analysis
Progression-Free survival
Human epidermal growth factor 2 negative carcinoma of breast (disorder)
treatment outcome
evaluation of the transparency committee
postmenopause
Stage IV Breast Cancer AJCC v6 and v7
Locally advanced breast cancer
HER2/Neu Negative
palbociclib
piperazines
pyridines
disease-free survival
---
http://kce.fgov.be/fr/publication/report/anticoagulation-et-fibrillation-auriculaire
2017
false
false
false
Belgium
French
anticoagulants
anticoagulants
atrial fibrillation
treatment outcome
stroke
continuity of patient care
Cost-Benefit analysis
medication adherence
risk assessment
hemorrhage
vitamin K
antivitamins K
Rivaroxaban
edoxaban
Dabigatran
apixaban
Factor Xa Inhibitors
antithrombins
belgium
technical report
drug information
comparative study
anticoagulants
economic evaluation
drug monitoring
new oral anticoagulant
indenes
4-hydroxycoumarins
pyridines
thiazoles
pyrazoles
pyridones
---
http://www.has-sante.fr/portail/jcms/c_2736733/fr/cabometyx
http://www.has-sante.fr/portail/jcms/c_2736733/fr/cabometyx-cabozantinib-inhibiteur-de-tyrosine-kinase
2017
false
false
false
France
French
treatment outcome
cabozantinib
anilides
pyridines
cabozantinib
carcinoma, renal cell
Advanced Malignant Neoplasm
Cabozantinib S-malate
receptor Protein-Tyrosine kinases
administration, oral
adult
protein kinase inhibitors
protein kinase inhibitors
survival analysis
evaluation of the transparency committee
clear cell renal cell carcinoma
guidelines for drug use
Tyrosine Kinase Inhibitors
cabozantinib
anilides
pyridines
---
http://www.has-sante.fr/portail/jcms/c_2658504/fr/lixiana-mtev
http://www.has-sante.fr/portail/jcms/c_2658504/fr/lixiana-mtev-edoxaban-anticoagulant-par-voie-orale
2016
false
false
false
France
French
evaluation of the transparency committee
deep vein thrombosis
deep vein thrombosis
recurrence
adult
administration, oral
pulmonary embolism
pulmonary embolism
edoxaban
edoxaban
edoxaban
treatment outcome
insurance, health, reimbursement
Factor Xa Inhibitors
Factor Xa Inhibitors
guidelines for drug use
venous thromboembolism
venous thrombosis
venous thrombosis
pyridines
thiazoles
pyridines
thiazoles
---
http://www.has-sante.fr/portail/jcms/c_2655911/fr/odomzo
https://www.has-sante.fr/portail/jcms/c_2655911/fr/odomzo-sonidegib-inhibiteur-de-hedgehog
2016
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
sonidegib
sonidegib
sonidegib
adult
carcinoma, basal cell
Locally Advanced Malignant Neoplasm
administration, oral
antineoplastic agents
antineoplastic agents
insurance, health, reimbursement
Hedgehog Signaling Pathway
Response Rate
survival analysis
Odomzo
guidelines for drug use
sonidegib
sonidegib
biphenyl compounds
pyridines
biphenyl compounds
pyridines
sonidegib
biphenyl compounds
pyridines
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/1065/850
2016
false
false
false
false
Canada
French
drug administration schedule
critical appraisal or critical reading
Drug-Eluting stents
drug therapy, combination
multicenter studies as topic
thrombosis
aspirin
aspirin
Prasugrel Hydrochloride
purinergic P2Y receptor antagonists
purinergic P2Y receptor antagonists
thienopyridine
platelet aggregation inhibitors
Drug-eluting coronary stent placement
hemorrhage
Coronary stent thrombosis
thienopyridine
stroke
myocardial infarction
time
platelet aggregation inhibitors
pyridines
pyridines
Clopidogrel
---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-inhibiteurs-de-la-voie-Hedgehog-vismodegib
2016
false
false
false
France
French
administration, oral
Drug-Related side effects and adverse reactions
guidelines for drug use
patients guideline
practice guideline
vismodegib
vismodegib
vismodegib
vismodegib
antineoplastic agents
antineoplastic agents
antineoplastic agents
carcinoma, basal cell
pregnancy
drug interactions
interdisciplinary communication
Hedgehog Signaling Pathway
signal transduction
hedgehog proteins
continuity of patient care
drug monitoring
HhAntag691
HhAntag691
HhAntag691
anilides
pyridines
anilides
pyridines
anilides
pyridines
---
http://www.has-sante.fr/portail/jcms/c_2621471/fr/cresemba
http://www.has-sante.fr/portail/jcms/c_2621471/fr/cresemba-isavuconazole-antifongique
2016
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
infusions, intravenous
isavuconazole
isavuconazole
isavuconazole
treatment outcome
antifungal agents
antifungal agents
aspergillosis
invasive aspergillosis
mucormycosis
adult
orphan drug production
guidelines for drug use
nitriles
pyridines
triazoles
nitriles
pyridines
triazoles
---
http://www.has-sante.fr/portail/jcms/c_2658576/fr/lixiana-avc-fanv
http://www.has-sante.fr/portail/jcms/c_2658576/fr/lixiana-avc-fanv-edoxaban-anticoagulant-par-voie-orale
2016
false
false
false
France
French
evaluation of the transparency committee
administration, oral
edoxaban
edoxaban
Factor Xa Inhibitors
Factor Xa Inhibitors
risk factors
adult
embolism
treatment outcome
edoxaban
insurance, health, reimbursement
atrial fibrillation
aged
guidelines for drug use
stroke
pyridines
thiazoles
pyridines
thiazoles
---
https://ansm.sante.fr/tableau-atu-rtu/cabometyx-20-mg-40-mg-et-60-mg-comprime-pellicule
2016
false
false
false
France
French
cabozantinib
cabozantinib
guidelines for drug use
summary of product characteristics
package leaflet
cabozantinib
seborrhea sicca
dandruff
compression, nos
tablets
pill, nos
dandruff
anilides
pyridines
anilides
pyridines
---
https://www.ema.europa.eu/medicines/human/EPAR/Cabometyx
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
cabozantinib
anilides
pyridines
cabozantinib
drug approval
europe
drug interactions
pregnancy
breast feeding
carcinoma, renal cell
Advanced Malignant Neoplasm
Cabozantinib S-malate
receptor Protein-Tyrosine kinases
administration, oral
tablets
adult
protein kinase inhibitors
protein kinase inhibitors
risk assessment
product surveillance, postmarketing
survival analysis
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
cabozantinib
anilides
pyridines
---
https://www.ema.europa.eu/medicines/human/EPAR/Ibrance
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
palbociclib
palbociclib
drug approval
europe
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
breast neoplasms
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic combined chemotherapy protocols
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
survival analysis
Progression-Free survival
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Human epidermal growth factor 2 negative carcinoma of breast (disorder)
palbociclib
piperazines
pyridines
disease-free survival
piperazines
pyridines
---
http://www.has-sante.fr/portail/jcms/c_2730782/fr/zolpidem-mylan
2016
false
false
false
France
French
evaluation of the transparency committee
zolpidem
pyridines
Zolpidem
---
http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-12-page2-fra.php#eriv
2016
false
false
false
Canada
French
English
pharmacovigilance note
vismodegib
vismodegib
child
adolescent
vismodegib
premature epiphyseal closure
bone diseases
HhAntag691
HhAntag691
anilides
pyridines
anilides
pyridines
Contraindications, Drug
---
https://www.revmed.ch/RMS/2016/RMS-N-542/Anticoagulants-oraux-directs-ACOD-une-aide-a-la-prescription-dans-la-pratique-quotidienne
2016
false
false
false
Switzerland
French
journal article
venous thromboembolism
antithrombins
administration, oral
atrial fibrillation
Evidence-Based medicine
guidelines for drug use
recurrence
venous thromboembolism
antithrombins
Direct factor Xa inhibitors
Factor Xa Inhibitors
Factor IIa
dabigatran etexilate
Dabigatran
Rivaroxaban
apixaban
edoxaban
drug interactions
continuity of patient care
clinical chemistry tests
kidney function tests
hemorrhage
surgical procedures, operative
heparin
antivitamins K
patient safety
factor IIa
prothrombin
pyrazoles
pyridones
pyridines
thiazoles
indenes
4-hydroxycoumarins
vitamin K
vitamin K
---
https://www.revmed.ch/RMS/2016/RMS-N-529/Anticoagulants-oraux-directs-quelques-considerations-pratiques
2016
false
false
false
Switzerland
French
journal article
administration, oral
anticoagulants
thromboembolism
thromboembolism
Direct factor Xa inhibitors
direct thrombin inhibitors
aged
neoplasms
liver cirrhosis
obesity
continuity of patient care
drug interactions
antidotes
stroke
treatment outcome
anticoagulants
Dabigatran
Rivaroxaban
apixaban
edoxaban
anticoagulants
Contraindications, Procedure
pyrazoles
pyridones
pyridines
thiazoles
Contraindications, Drug
---
https://www.ema.europa.eu/medicines/human/EPAR/Praxbind
2015
false
false
false
United Kingdom
French
English
summary of product characteristics
package leaflet
idarucizumab
idarucizumab
Anticoagulant reversal therapy
anticoagulants
emergency treatment
hemorrhage
surgical procedures, operative
hemorrhage
hemorrhage
adult
drug evaluation
syndication feed
drug approval
treatment outcome
europe
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
product surveillance, postmarketing
injections, intravenous
infusions, intravenous
idarucizumab
Dabigatran
reversal of oral anticoagulants
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
pyridines
---
https://www.ema.europa.eu/medicines/human/EPAR/Cresemba
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
isavuconazole
isavuconazole
antifungal agents
antifungal agents
drug approval
europe
invasive aspergillosis
adult
aspergillosis
mucormycosis
infusions, intravenous
administration, oral
product surveillance, postmarketing
drug interactions
breast feeding
pregnancy
14-alpha demethylase inhibitors
14-alpha demethylase inhibitors
drug evaluation, preclinical
drug compounding
isavuconazole
nitriles
pyridines
triazoles
nitriles
pyridines
triazoles
---
http://www.has-sante.fr/portail/jcms/c_2566483/fr/stivarga
http://www.has-sante.fr/portail/jcms/c_2566483/fr/stivarga-regorafenib-inhibiteur-de-proteine-kinase
2015
false
France
French
regorafenib
regorafenib
regorafenib
administration, oral
treatment outcome
insurance, health, reimbursement
adult
neoplasm metastasis
antineoplastic agents
antineoplastic agents
Progression-Free survival
evaluation of the transparency committee
Unresectable Malignant Neoplasm
gastrointestinal stromal tumors
guidelines for drug use
protein kinase inhibitors
protein kinase inhibitors
disease-free survival
phenylurea compounds
pyridines
phenylurea compounds
pyridines
---
https://www.ema.europa.eu/medicines/human/EPAR/Odomzo
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
sonidegib
sonidegib
adult
Unresectable Malignant Neoplasm
Locally Advanced Malignant Neoplasm
carcinoma, basal cell
administration, oral
Hedgehog Signaling Pathway
drug monitoring
product surveillance, postmarketing
drug interactions
pregnancy
contraception
teratogens
breast feeding
survival analysis
drug evaluation, preclinical
sonidegib
sonidegib
sonidegib
biphenyl compounds
pyridines
biphenyl compounds
pyridines
---
https://www.has-sante.fr/portail/jcms/c_2579446/fr/zontivity-vorapaxar-antiagregant-plaquettaire
2015
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
drug therapy, combination
vorapaxar
vorapaxar
vorapaxar
adult
myocardial infarction
platelet aggregation inhibitors
platelet aggregation inhibitors
aspirin
Atherothrombosis
Atherothrombosis prophylaxis
atherosclerosis
thrombosis
Product containing vorapaxar in oral dose form (medicinal product form)
lactones
pyridines
lactones
pyridines
Clopidogrel
---
http://www.has-sante.fr/portail/jcms/c_2015058/fr/quelle-place-pour-les-benzodiazepines-dans-linsomnie-fiche-bum
2015
false
true
false
France
French
guidelines for drug use
sleep initiation and maintenance disorders
benzodiazepines
hypnotics and sedatives
benzodiazepines
hypnotics and sedatives
adult
aged
Duration of treatment (qualifier value)
time factors
lormetazepam
benzodiazepine derivatives
estazolam
nitrazepam
triazulenone
zopiclone
temazepam
withdrawing treatment
Therapy cessation
lorazepam
lorazepam
pyridines
piperazines
azabicyclo compounds
Zolpidem
---
https://www.ema.europa.eu/medicines/human/EPAR/Zontivity
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
vorapaxar
vorapaxar
vorapaxar
platelet aggregation inhibitors
platelet aggregation inhibitors
administration, oral
receptor, par-1
receptors, thrombin
atherosclerosis
thrombosis
Atherothrombosis
myocardial infarction
stroke
adult
drug therapy, combination
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Product containing vorapaxar in oral dose form (medicinal product form)
lactones
pyridines
lactones
pyridines
---
https://www.ema.europa.eu/medicines/human/EPAR/Akynzeo
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
drug approval
netupitant
netupitant
palonosetron, combinations
palonosetron hydrochloride
palonosetron hydrochloride
Drug-Related side effects and adverse reactions
nausea
nausea
antineoplastic agents
vomiting
vomiting
administration, oral
serotonin 5-HT3 receptor antagonists
serotonin 5-HT3 receptor antagonists
Neurokinin-1 receptor antagonists
Neurokinin-1 receptor antagonists
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
netupitant, palosentron drug combination
netupitant, palosentron drug combination
pyridines
pyridines
isoquinolines
quinuclidines
isoquinolines
quinuclidines
Palonosetron
Palonosetron
---
https://www.ema.europa.eu/medicines/human/EPAR/Lixiana
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
edoxaban
edoxaban
Edoxaban Tosylate
Edoxaban Tosylate
drug approval
europe
product surveillance, postmarketing
administration, oral
stroke
embolism
adult
risk factors
atrial fibrillation
deep vein thrombosis
deep vein thrombosis
recurrence
pulmonary embolism
pulmonary embolism
drug interactions
pregnancy
breast feeding
hemorrhage
edoxaban
Edoxaban Tosylate
hemorrhage
Factor Xa Inhibitors
Factor Xa Inhibitors
Factor Xa Inhibitors
edoxaban
drug evaluation, preclinical
venous thrombosis
venous thrombosis
pyridines
thiazoles
pyridines
thiazoles
pyridines
thiazoles
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=127753&nom=Éthyl-5+méthyl-2+pyridine
Canada
toxicological data sheet
pyridines
pyridine
alcoholism
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=10157&nom=Méthyl-2+pyridine
Canada
toxicological data sheet
pyridine
pyridines
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=1438&nom=Pyridine
Canada
toxicological data sheet
pyridine
pyridines
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=150847&nom=Amino-3+pyridine
Canada
toxicological data sheet
pyridines
pyridine
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=265&nom=Amino-2+pyridine
Canada
toxicological data sheet
pyridines
pyridine
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=192773&nom=Amino-2+méthyl-3+pyridine
Canada
toxicological data sheet
pyridines
pyridine
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=196113&nom=Amino-2+méthyl-6+pyridine
Canada
toxicological data sheet
pyridine
pyridines
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=779413&nom=Méthyl-1+phényl-4+tétrahydro-1,2,3,6+pyridine
Canada
toxicological data sheet
pyridine
pyridines
---
http://www.sciencedirect.com/science/article/pii/S0755498214002590
2014
false
false
false
France
French
atrial fibrillation
anticoagulants
administration, oral
anticoagulants
drug interactions
journal article
dabigatran etexilate
rivaroxaban
apixaban
apixaban
edoxaban
warfarin
factor xa
antithrombins
treatment outcome
renal insufficiency
age factors
Direct current cardioversion (procedure)
myocardial infarction
surgical procedures, operative
Factor Xa Inhibitors
anticoagulotherapy
Dabigatran
Rivaroxaban
pyridines
pyrazoles
pyridones
thiazoles
---
http://www.has-sante.fr/portail/jcms/c_1721873/fr/erivedge-vismodegib-antineoplasique
2014
false
false
false
France
French
English
guidelines for drug use
evaluation of the transparency committee
treatment outcome
administration, oral
vismodegib
vismodegib
vismodegib
antineoplastic agents
antineoplastic agents
carcinoma, basal cell
neoplasm metastasis
adult
insurance, health, reimbursement
HhAntag691
HhAntag691
anilides
pyridines
anilides
pyridines
---
http://www.cochrane.org/fr/CD007744/tolerabilite-des-inhibiteurs-selectifs-de-la-cyclo-oxygenase-2-cox-2-utilises-dans-le-traitement-des-manifestations-rhumatologiques-des-maladies-inflammatoires-de-lintestin
2014
false
false
false
France
United Kingdom
French
review of literature
cyclooxygenase 2 inhibitors
musculoskeletal diseases
french abstract
treatment outcome
Celecoxib
Celecoxib
celecoxib
etoricoxib
inflammatory bowel diseases
cyclooxygenase 2 inhibitors
pyridines
sulfones
pyridines
sulfones
Etoricoxib
Etoricoxib
---
http://www.has-sante.fr/portail/jcms/c_2007291/fr/cometriq
http://www.has-sante.fr/portail/jcms/c_2007291/fr/cometriq-cabozantinib-inhibiteur-de-tyrosine-kinase
2014
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
anilides
anilides
pyridines
pyridines
receptor Protein-Tyrosine kinases
neoplasm metastasis
adult
thyroid cancer, medullary
treatment outcome
survival analysis
antineoplastic agents
antineoplastic agents
administration, oral
insurance, health, reimbursement
cabozantinib
late
Progression-Free survival
protein kinase inhibitors
protein kinase inhibitors
cabozantinib
cabozantinib
Tyrosine Kinase Inhibitors
disease-free survival
thyroid neoplasms
---
https://www.jle.com/fr/revues/medecine/met/e-docs/00/04/99/39/resume.phtml
2014
false
France
French
atrial fibrillation
anticoagulants
journal article
thrombosis
vitamin K
drug interactions
practice guideline
aged
risk assessment
apixaban
edoxaban
pyridines
thiazoles
pyrazoles
pyridones
antithrombins
anticoagulotherapy
Rivaroxaban
Dabigatran
antivitamins K
indenes
4-hydroxycoumarins
---
http://www.has-sante.fr/portail/jcms/c_1743045/fr/stivarga
2014
false
France
French
regorafenib
regorafenib
regorafenib
administration, oral
treatment outcome
insurance, health, reimbursement
adult
neoplasm metastasis
colorectal neoplasms
antineoplastic agents
antineoplastic agents
Progression-Free survival
evaluation of the transparency committee
disease-free survival
phenylurea compounds
pyridines
phenylurea compounds
pyridines
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00212
2013
false
false
false
Canada
Product containing precisely vismodegib 150 milligram/1 each conventional release
oral capsule (clinical drug)
vismodegib
vismodegib
drug information
HhAntag691
anilides
pyridines
---
https://rmlg.uliege.be/article/2463
2013
false
true
false
Belgium
French
journal article
venous thromboembolism
venous thromboembolism
venous thromboembolism
hematologic agents
factor xa
thiazoles
pyridines
pyridines
pyridines
pyridines
thiazoles
thiazoles
thiazoles
venous thromboembolism
edoxaban
warfarin
---
http://www.cochrane.org/fr/CD004309
2013
United Kingdom
France
French
meta-analysis
administration, oral
treatment outcome
adult
acute disease
pain, postoperative
cyclooxygenase 2 inhibitors
pyridines
sulfones
french abstract
Etoricoxib
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=687996&nom=FLUAZIFOP%2DBUTYL
Canada
French
pyridines
fluazifop-butyl
pyridines
toxicological data sheet
---
https://www.ema.europa.eu/medicines/human/EPAR/Nexavar
2012
false
United Kingdom
English
French
phenylurea compounds
phenylurea compounds
niacinamide
syndication feed
treatment outcome
drug evaluation
orphan drug production
carcinoma, renal cell
pyridines
benzenesulfonates
antineoplastic agents
protein kinase inhibitors
sorafenib
pyridines
benzenesulfonates
antineoplastic agents
protein kinase inhibitors
sorafenib tosylate
sorafenib tosylate
drug evaluation
summary of product characteristics
package leaflet
Sorafenib
Sorafenib
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=292524&nom=Pyrithione+de+zinc
Canada
French
pyridines
zinc
pyrithione zinc
toxicological data sheet
---
https://www.minerva-ebp.be/fr/article/621
false
false
minerva-ebm.be
Belgium
French
pyridines
cyclooxygenase inhibitors
sulfones
diclofenac
gastrointestinal diseases
osteoarthritis
arthritis, rheumatoid
anti-inflammatory agents, non-steroidal
critical appraisal or critical reading
comparative study
---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%20155
France
French
pyridines
pyridines
pyridines
pyridines
pyridines
occupational exposure
occupational diseases
reference values
guidelines
toxicological data sheet
---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%20152
France
French
pyridines
pyridines
pyridines
pyridines
pyridines
occupational exposure
occupational diseases
reference values
2,6-lutidine
guidelines
toxicological data sheet
---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%2085
France
French
pyridines
pyridines
pyridines
pyridines
pyridines
occupational exposure
occupational diseases
reference values
guidelines
toxicological data sheet
---
http://unt-ori2.crihan.fr/unspf/2010_Lyon1_Nebois_heterocycliques_aromatiques_monocycliques.pdf
2010
true
false
true
France
educational course
education, pharmacy
chemistry, organic
imidazoles
heterocyclic compounds, 1-ring
pyrroles
pyridines
---
http://www.has-sante.fr/portail/jcms/c_825456/arcoxia-120-mg-etoricoxib-ains
http://www.has-sante.fr/portail/jcms/c_825455/synthese-d-avis-arcoxia-120-mg-ct-5948
http://www.has-sante.fr/portail/jcms/c_799058/arcoxia-120-mg-ct-5948
2009
France
French
pyridines
sulfones
cyclooxygenase inhibitors
anti-inflammatory agents, non-steroidal
gout
etoricoxib
evaluation of the transparency committee
guidelines for drug use
Etoricoxib
---
http://www.has-sante.fr/portail/jcms/c_799056/arcoxia-30-et-60-mg-ct-5948
http://www.has-sante.fr/portail/jcms/c_825451/arcoxia-30-et-60-mg-etoricoxib-ains
2009
France
French
osteoarthritis
pyridines
sulfones
cyclooxygenase inhibitors
anti-inflammatory agents, non-steroidal
etoricoxib
evaluation of the transparency committee
guidelines for drug use
Etoricoxib
---
http://www.lecrat.eu/?s=Zolpidem
2009
France
French
pyridines
pregnancy
hypnotics and sedatives
zolpidem
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3638890
2008
France
French
zolpidem tartrate
pyridines
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
zolpidem
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3610302
2008
France
French
zolpidem tartrate
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
pyridines
zolpidem
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3602604
2008
France
French
pyridines
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3602596
2008
France
French
tablets
administration, oral
drug prescriptions
legislation, drug
drugs, generic
pyridines
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3645571
2008
France
French
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
pyridines
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3645542
2008
France
French
pyridines
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3645051
2008
France
French
pyridines
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3621599
2008
France
French
pyridines
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3671284
2008
France
French
pyridines
tablets
drugs, generic
administration, oral
drug prescriptions
legislation, drug
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3674934
2008
France
French
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
pyridines
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3674928
2008
France
French
tablets
administration, oral
drugs, generic
drug prescriptions
pyridines
legislation, drug
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3390361
2008
France
French
pyridines
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
zolpidem
hypnotics and sedatives
drug information
Zolpidem
---
http://www.meddispar.fr/medicaments/3692524
2008
France
French
tipranavir
pyrones
administration, oral
capsules
pyridines
drug prescriptions
legislation, drug
tipranavir
drug information
---
http://www.lecrat.eu/?s=Carbinoxamine
2008
France
French
infant, newborn
pyridines
histamine h1 antagonists
pregnancy
carbinoxamine
carbinoxamine
pyridines
drug information
---
http://www.meddispar.fr/Medicaments/ZOLPIDEM-MYLAN-10-P-14/(type)/letter/(value)/Z/(cip)/3400936450974
2008
true
France
French
pyridines
tablets
administration, oral
drugs, generic
drug prescriptions
legislation, drug
zolpidem
zolpidem tartrate
drug information
Zolpidem
---
https://www.minerva-ebp.be/fr/article/651
2007
false
false
minerva-ebm.be
Belgium
French
comparative study
arthritis, rheumatoid
anti-inflammatory agents, non-steroidal
diclofenac
sulfones
pyridines
cyclooxygenase 2 inhibitors
diclofenac
sulfones
pyridines
cyclooxygenase 2 inhibitors
anti-inflammatory agents, non-steroidal
cardiovascular diseases
critical appraisal or critical reading
---
https://rmlg.uliege.be/article/1089
2004
Belgium
French
pyridines
sulfones
cyclooxygenase inhibitors
journal article
Etoricoxib
---
https://www.cadth.ca/sites/default/files/pdf/108_No26_etoricoxib_edrug_f.pdf
2002
Canada
French
pyridines
sulfones
cyclooxygenase inhibitors
dysmenorrhea
pain
arthritis
etoricoxib
drug evaluation
comparative study
---
